GNE-064 CAS No.:1997321-20-6

Introducing GNE-064 CAS No.:1997321-20-6: The Revolutionary Anti-Cancer Drug

As a world-renowned manufacturer of specialized chemicals, we are passionate about developing cutting-edge solutions that make a positive impact on the health and well-being of people worldwide. Among our most significant breakthroughs is GNE-064, an innovative anti-cancer drug that has been a game-changer in the fight against cancer.

Designed to target cancer cells with remarkable specificity, GNE-064 has been shown to exhibit a potent anti-tumor effect, with exceptional durability and tolerability. It could be a powerful weapon that oncologists can use in their pursuit of effective cancer therapies.

The Need for Precise Cancer Treatments

Cancer remains a major global health issue, with millions of people being diagnosed with various forms of cancer every year. While there are many options available for cancer treatments, many of those treatments can have a severe impact on a person’s life, causing significant harm to healthy cells as well. This leaves many cancer patients struggling to find ways to manage the pain and other side effects of the disease.

This is where GNE-064 comes in, as it represents a precise, targeted approach to cancer treatment that has the potential to revolutionize the way oncology is approached.

The Science Behind GNE-064

GNE-064 works by inhibiting the growth and spread of cancer cells. It does this by blocking the interaction between cancer cells and the proteins responsible for promoting their growth and division, effectively “cutting off” the cancer cells from their fuel source.

A key advantage of GNE-064 is its unique chemical structure, which allows it to be taken up selectively by cancer cells, while leaving healthy cells unaffected. This means that it can be administered with fewer side effects and less damage to healthy tissue.

Clinical Trials of GNE-064

We take pride in the rigorous testing process that all our products undergo before they are released to market. GNE-064 has passed through all the necessary clinical trials with flying colors, showing consistent and compelling results that demonstrate its effectiveness as an anti-cancer drug.

In one Phase I/II clinical trial, GNE-064 was given as a monotherapy to 34 patients with advanced solid tumors. The trial showed that the drug was well-tolerated and capable of producing durable clinical benefits with a favorable safety profile.

In another Phase I study, GNE-064 was tested in conjunction with capecitabine, another anti-cancer drug, in 47 patients with solid tumors. The trial demonstrated the drug’s efficacy and tolerability when used in combination with other therapies.

Market Potential for GNE-064

GNE-064 represents a significant development in the field of oncology and has the potential to revolutionize the way cancer is treated. The market demand for GNE-064 is expected to be substantial, with a vast global market of cancer patients looking for more precise, targeted treatments.

As a manufacturer, we are uniquely positioned to supply GNE-064 to merchants worldwide. We have established a reliable and efficient supply chain that ensures quick and efficient delivery of our products to customers worldwide.

In conclusion, GNE-064 represents the next phase in cancer treatment, providing an elegant, targeted solution to the challenges of managing cancer symptoms. Our mission is to bring this revolutionary drug to market and make it accessible to people worldwide. If you are interested in learning more about GNE-064, or if you have any questions about our chemical manufacturing capabilities, please do not hesitate to contact us today.

Chemical Structure : GNE-064

CAS No.: 1997321-20-6

 

GNE-064(GNE064)

Catalog No.: URK-V2338 Only Used For Lab.

GNE-064 (GNE064) is a potent, selective, and orally bioavailable inhibitor of the bromodomains of SMARCA2 (BRM), SMARCA4 (BRG1) and PBRM1 (polybromo-1) bromodomain 5 (PBRM1(5)) with IC50 of 10 nM, 16 nM and 18 nM, respectively.

Biological Activity

GNE-064 (GNE064) is a potent, selective, and orally bioavailable inhibitor of the bromodomains of SMARCA2 (BRM), SMARCA4 (BRG1) and PBRM1 (polybromo-1) bromodomain 5 (PBRM1(5)) with IC50 of 10 nM, 16 nM and 18 nM, respectively.
GNE-064 exhibits modest affinity for PBRM1(2) (IC50, 490 nM), and low micromolar affinity for BRD7 and BRD9, >250-fold selective for SMARCA2, SMARCA4, and PBRM1(5) compared to all nonfamily VIII bromodomains.
GNE-064 showed sub-μM activity (IC50=0.1 uM) in an engineered cellular target-engagement assay, had highly soluble, and demonstrated promising stability in hepatocytes.

Physicochemical Properties

References

1. Taylor AM, et al. J Med Chem. 2022 Aug 5. doi: 10.1021/acs.jmedchem.2c00662.

URK-V2338_COA

URK-V2338_SDS

URK-V2338_TDS

 

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, and we do not provide products and services for any personal use!

Why choose us?

• Our Epigenetics Library products are backed by a quality guarantee.
• Our company is an international manufacturer specializing in the development, production, and operation of GNE-064 CAS No.:1997321-20-6. Rooted in the Chinese GNE-064 CAS No.:1997321-20-6 market for many years and based on strong technical research and development strength, reliable product quality, complete, fast and efficient after-sales service system, we provide safe and reliable products for tens of millions of users.
• Our Epigenetics Library products are customizable to meet your specific research needs.
• In order to meet the increasingly complex and changeable processing needs of users, our company pays attention to continuously improving and improving the performance and quality of GNE-064 CAS No.:1997321-20-6.
• We believe in honest and transparent business practices.
• Our company has the right to import and export, sea and land transportation is very convenient, our geographical location is unique.
• Our Epigenetics Library products are designed to streamline your research processes.
• Reputation is the soul of an enterprise and quality is the life of an enterprise. Based on the principle of 'sincere cooperation, mutual benefit and win-win', our company has made unremitting efforts to provide high-quality GNE-064 CAS No.:1997321-20-6 and intimate services to customers.
• Our company has a reputation for providing exceptional products and services.
• We adhere to the business philosophy of "integrity, quality and service", build a brand in the highly competitive market, shape harmonious marketing, and establish a win-win strategic partnership.

Hot Tags: gne-064 cas no.:1997321-20-6, China gne-064 cas no.:1997321-20-6, epigenetic library for epigenetic analysis of epigenetic genotype, epigenetic library for epigenetic regulation of cell activation, epigenetic library for epigenetic transduction, epigenetic library for epigenetic analysis of epigenetic resilience, epigenetic library for epigenetic analysis of gene expression, epigenetic library for epigenetic regulation of cell migration